Home Medicine Point-of-care determination of neonatal bilirubin with the blood gas analyzer RapidLab 1265
Article
Licensed
Unlicensed Requires Authentication

Point-of-care determination of neonatal bilirubin with the blood gas analyzer RapidLab 1265

  • Caroline Mielsch , Andrea Zimmermann , Dieter Wagner , Bianca Matthes , Harald Schlebusch and Peter B. Luppa
Published/Copyright: July 7, 2010

Abstract

Background: The aim of the study was to evaluate the comparability of the new neonatal bilirubin method on the RapidLab 1265 blood gas analyzer. This point-of-care testing (POCT) device has the option for the determination of neonatal bilirubin, making it potentially valuable for use in neonate intensive care units or in outpatient ambulances.

Methods: We paired 240 patient samples for intermethod comparisons between the new POCT method and the routine laboratory method (Vitros 350 chemistry system with BuBc slide). In parallel, a transcutaneous jaundice meter (JM-103) was applied to the newborns. Low birthweight and premature neonates were excluded from the trial. The turn-around-time (TAT) for the POCT method was also compared with the routine method, and the practicality of the new analyzer was evaluated for clinical purposes.

Results: Bilirubin measurements using the RapidLab 1265 are suitable for the application in newborns. For imprecision, coefficients of variation between 5.6% and 23% were found. The correlation between the Vitros 350 (x) and RapidLab 1265 (y) was y=1.0x–0.1 (r=0.91), with a mean bias of +0.1 mg/dL and a 95% limit of agreement of ±2.5 mg/dL. As in all POCT methods, the TAT was significantly lower than that of the core laboratory.

Conclusions: In contrast to the JM-103, the results of the RapidLab 1265 correlated closely with the Vitros 350, although occasional results of both methods were more different than expected. In general, the RapidLab 1265 blood gas analyzer provides clinically useful bilirubin results using neonatal whole blood samples, although imprecision data are higher than for the laboratory method. The POCT device is suitable for neonatal intensive care units after thoroughly training the employees that will use the device.

Clin Chem Lab Med 2010;48:1455–61.


Corresponding author: Peter B. Luppa, Institut für Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar der Technischen Universität München, Ismaninger Str. 22, 81675 Munich, Germany Phone: +49 89 4140 4759, Fax: +49 89 4140 4875,

Received: 2010-2-8
Accepted: 2010-4-15
Published Online: 2010-07-7
Published in Print: 2010-10-01

©2010 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Editorial
  2. Darwinian evolution or regression? The fate of laboratory professionals
  3. Review
  4. Automated reticulocyte counting: state of the art and clinical applications in the evaluation of erythropoiesis
  5. Minireview
  6. Laboratory diagnostics in acute poisoning: critical overview
  7. Opinion Papers
  8. On the origins of physicians: Darwinian or Lamarckian evolution?
  9. Observed, unknown distributions of clinical chemical quantities should be considered to be log-normal: a proposal
  10. Guidelines and Recommendations
  11. Development and description of GETT: a Genetic testing Evidence Tracking Tool
  12. Genetics and Molecular Diagnostics
  13. DNA sequencing errors in molecular diagnostics of filamin myopathy
  14. High resolution melting for the identification of mutations in the iron responsive element of the ferritin light chain gene
  15. General Clinical Chemistry and Laboratory Medicine
  16. Detection of serum free light chains: the problem with antigen excess
  17. Hepcidin concentrations and iron homeostasis in preeclampsia
  18. Automated assay for non-transferrin-bound iron in serum samples
  19. A simple liquid chromatography-tandem mass spectrometry method for urinary free cortisol analysis: suitable for routine purpose
  20. Evaluation of a multiplex assay for adipokine concentrations in obese children
  21. The use of serial patient blood gas, electrolyte and glucose results to derive biologic variation: a new tool to assess the acceptability of intensive care unit testing
  22. Point-of-care determination of neonatal bilirubin with the blood gas analyzer RapidLab 1265
  23. The effect of pre-analytical variables on light transmittance aggregometry in citrated platelet-rich plasma from healthy subjects
  24. Cancer Diagnostics
  25. Clinical significance of serum macrophage-colony stimulating factor (M-CSF) in esophageal cancer patients and its comparison with classical tumor markers
  26. VKORC1 haplotypes influence the performance characteristics of PIVKAII for screening of hepatocellular carcinoma
  27. Serum soluble tumour necrosis factor receptor type I concentrations independently predict prognosis in patients with breast cancer
  28. Variations in systemic biomarkers of oxidative/nitrosative stress and DNA damage before and during the consequent two cycles of chemotherapy in breast cancer patients
  29. Spurious increase in serum chromogranin A: the role of heterophilic antibodies
  30. Infectious Diseases
  31. Identification and evaluation of a new nucleic acid amplification test target for specific detection of Mycobacterium tuberculosis
  32. Application of an oligonucleotide microarray-based nano-amplification technique for the detection of fungal pathogens
  33. Liquid chromatography-tandem mass spectrometry method for simultaneous quantification of four triazole antifungal agents in human plasma
  34. Evaluation of two sirolimus assays using the ARCHITECT-i1000® CMIA or RxL® ACMIA methods in comparison with the IMx® MEIA method
  35. Widespread use of point-of-care testing is irreconcilable with the present-day quest for safety
  36. Congress Abstracts
  37. 3rd Annual Congress of the Austrian Society for Laboratory Medicine and Clinical Chemistry Salzburg, Austria, 27-30 October 2010
Downloaded on 12.2.2026 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2010.279/html
Scroll to top button